drug costs

Research Reports

Drug Costs vs Probability of Survival in Lung Cancer: Impact of Dosage, Duration, and Immune Checkpoint Inhibitor Combinations

06/18/2019

Helmy M Guirgis, MD

Abstract: Clinical guidelines and pathways recommend use of immune checkpoint inhibitors (ICI) in first- and second-line treatment of advanced/metastatic non-small cell lung cancer (amNSCLC). There is an unmet need...

...

06/18/2019

Journal of Clinical Pathways

Counterpoint

To Increase Innovation and Make Drugs More Affordable, Deregulate

10/27/2015

David R. Henderson, PhD

Charles L. Hooper, MS

Are there ways to make drugs more affordable without reducing the incentive to innovate? Dr. Owens makes two principal claims with which we agree. Any dialogue about the rising cost of cancer drugs must, as the...

Are...

10/27/2015

Journal of Clinical Pathways